Veysel KAYSER, Hervé PINTON, Jean-François SALUZZO, Bernhardt L. TROUT, Alain FRANÇON

2710

Rational design of rabies vaccine formulation for enhanced stability

Rational design of rabies vaccine formulation for enhanced stability

Background/aim: Vaccines are often lyophilized in order to retain their stability and efficacy for a longer period of time. However, the same lyophilization process may also cause a major degradation of the vaccine, especially during early phases of manufacturing, leading to a loss of potency of the product. Many viral diseases, such as rabies, are acute and fatal unless the vaccine is administered prior to exposure or the onset of symptoms in the case of postexposure treatment. Materials and methods: We investigated the effect of lyophilization on the stability of the virus structure during rabies vaccine manufacturing using dynamic light scattering and transmission electron microscopy. Results: Our results indicate that some viruses lose their stability and efficacy in the course of lyophilization if the pH of the cell culture medium is controlled by solvated CO2because the structure of the rabies virus is very sensitive to the solution pH: the virus either aggregates or its shape is deformed at low solution pH, whereas at high pH empty capsid shells are formed. Conclusion: Based on our findings, we developed a new formulation for the rabies vaccine that is stable in different buffers owing to the prevention of pH upshift upon lyophilization.
PDF

___

  • 1. Sellal F, Stoll-Keller F. Rabies: ancient yet contemporary cause of encephalitis. Lancet 2005; 365: 921-923.
  • 2. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies reexamined. Lancet Infect Dis 2002; 2: 327-343.
  • 3. Crick J. Rabies virus genome. In: Kuwert E, Merieux C, Koprowski H, Bogel K, editors. Rabies in the Tropics. Berlin, Germany: Springer-Verlag; 1985. pp. 13-20.
  • 4. Cox JH, Dietzschold B, Schneider LG. Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun 1977; 16: 754-759.
  • 5. Dietzschold B, Cox J, Schneider G. Structure and function of rabies virus glycoprotein. Dev Biol Stand 1978; 40: 45-55.
  • 6. Dietzschold B, Cox JH, Schneider LG, Wiktor TJ, Koprowski H. Isolation and purification of a polymeric form of the glycoprotein of rabies virus. J Gen Virol 1978; 40: 131-139.
  • 7. Gaudin Y, Ruigrok RWH, Brunner J. Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism. J Gen Virol 1995; 76: 1541-1556.
  • 8. Gaudin Y, Tuffereau C, Durrer P, Brunner J, Flamand A, Ruigrok R. Rabies virus-induced membrane fusion. Mol Membr Biol 1999; 16: 21-31.
  • 9. Maillard A, Domanski M, Brunet P, Chaffotte A, Guittet E, Gaudin Y. Spectroscopic characterization of two peptides derived from the stem of rabies virus glycoprotein. Virus Res 2003; 93: 151-158.
  • 10. Roche S, Gaudin Y. Characterization of the equilibrium between the native and fusion-inactive conformation of rabies virus glycoprotein indicates that the fusion complex is made of several trimers. Virology 2002; 297: 128-135.
  • 11. Weissenhorn W, Hinz A, Gaudin Y. Virus membrane fusion. FEBS Lett 2007; 581: 2150-2155.
  • 12. Madora H, England J. Rabies virus protein synthesis in infected BHK-21 cells. J Virol 1977; 22: 102-112.
  • 13. Public Health England. Human Rabies Vaccines. London, UK: Public Health England.
  • 14. Galazka A, Milstein J, Kartoglu U, Zaffran M. Temperature Sensitivity of Vaccines. WHO/IVB/06.10. Geneva, Switzerland: WHO; 2006.
  • 15. Babiuk S, Skowronski DM, De Serres G, HayGlass K, Brunham RC, Babiuk L. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol 2004; 72: 138-142.
  • 16. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011; 100: 354-387.
  • 17. Galazka A, Milstien J, Zaffran M. Thermostability of Vaccines. WHO/GPV/98.07. Geneva, Switzerland: WHO; 1998.
  • 18. Dietzschold ML, Faber M, Mattis JA, Pak KY, Schnell MJ, Dietzschold B. In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. Vaccine 2004; 23: 518-524.
  • 19. Wiktor TJ, Atanasiu P, Bahmanyar M, Boegel K, Cox JH, Diaz AM, Fitzgerald EA, Kuwert E, Netter R, Selimov M et al. Comparison studies on potency tests for rabies vaccines. Dev Biol Stand 1978; 40: 171-178.
  • 20. Barth R, Diderrich G, Weinmann E. NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine 1988; 6: 369-377.
  • 21. Michalski F, Parks NF, Sokol F, Clark HF. Thermal inactivation of rabies and other rhabdoviruses: stabilization by the chelating agent ethylenediaminetetraacetic acid at physiological temperatures. Infect Immun 1976; 14: 135-143.
  • 22. Blanche F, Cameron B, Somarriba S, Maton L, Barbot A, Guillemin T. Stabilization of recombinant adenovirus: sitedirected mutagenesis of key asparagine residues in the hexon protein. Anal Biochem 2001; 297: 1-9.
  • 23. Johnston JJ, Primus TM, Buettgenbach T, Furcolow CA, Goodall MJ, Slate D, Chipman RB, Snow JL, DeLiberto TJ. Evaluation and significance of tetracycline stability in rabies vaccine baits. J Wildlife Dis 2005; 41: 549-558.
  • 24. Rooijakkers EJM, Nieuwenhuijs JHM, Vermeulen AA, van Steenis G, Osterhaus ADME. Potency of veterinary rabies vaccines in the Netherlands: a case for continued vigilance. Vet Quart 1996; 18: 146-150.
  • 25. Neurath AR, Vernon SK, Dobkin MB, Rubin BA. Characterization of subviral components resulting from treatment of rabies virus with tri(n-butyl) phosphate. J Gen Virol 1972; 14: 33-48.
  • 26. Vernon SK, Neurath AR, Rubin BA. Electron microscopic studies on the structure of rabies virus. J Ultra Mol Struct R 1972; 41: 29-42.
  • 27. Lee KKH, Sahin YZ, Neeleman R, Trout BL, Kayser V. Quantitative determination of the surfactant-induced split ratio of influenza virus by fluorescence spectroscopy. Hum Vaccin Immunother 2016; 12: 1757-1765.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Arşiv
Sayıdaki Diğer Makaleler

Mahmut UĞURLU, Mehmet Atif Erol AKSEKİLİ, Berat Meryem ALKAN, Halil KARA, Ceyhun ÇAĞLAR

Ayşe BUT, Meltem Arzu YETKİN, Dilek KANYILMAZ, Halide ASLANER, Aliye BAŞTUĞ, Adalet AYPAK, Pinar ÖNGÜRÜ, Esragül AKINCI, Nevzat Mehmet MUTLU, Hurrem BODUR

Frequency of human parvovirus 4 (PARV4) viremia among HBV-infected patients and healthy donors in Shiraz, Iran

Fereshte AMIRAHMADI, Jamal SARVARI, Seyed Younes HOSSEINI, Neda PIRBONYEH, Ali Akbar GORZIN

Sezin ÜNAL, Nuriye Ebru ERGENEKON, Ebru KAZANCI, Selma AKTAŞ, Ferit KULALI, İbrahim Murat HIRFANOĞLU, Canan TÜRKYILMAZ, Yildiz ATALAY

Hakan UZUN, Ozan BİTİK, Yahya BALTU, Mehmet DADACI, Aycan Uğur KAYIKÇIOĞLU

CANER YÜRÜYEN, Yeşim GÜROL, Sabire Ferda KALEAĞASIOĞLU, ELİF ÇİĞDEM KASPAR, Gülden YILMAZ

Ayhan AŞKIN, Korhan Bariş BAYRAM, Ümit Seçil DEMİRDAL, Emel ATAR, Çiğdem Arifoğlu KARAMAN, Ece GÜVENDİ, ALİYE TOSUN

Social support and quality of life in a group of cancer patients (Ankara, Turkey)*

Birgül PİYAL, Recep AKDUR, Mustafa Soner YILMAZ

Sevgi AKARSU, Özlem ÖZBAĞÇIVAN, Necla DOLAŞ, Şebnem AKTAN

Veysel KAYSER, Alain FRANCON, Herve PINTON, Jean-francois SALUZZO, Bernhardt L. TROUT